Cargando…
Management and Outcomes of COVID – 19 Associated Cerebral Venous Sinus Thrombosis
BACKGROUND: Systemic hyper-coagulabilty leading to micro and macro thrombosis is a known complication of Coronavirus disease – 2019(COVID -19). The postulated mechanism appears to be the viral activation of endothelium, triggering the coagulation pathways. Thrombosis of the cerebral veins and sinuse...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier Inc.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8743463/ https://www.ncbi.nlm.nih.gov/pubmed/35091267 http://dx.doi.org/10.1016/j.jstrokecerebrovasdis.2022.106306 |
_version_ | 1784629910781820928 |
---|---|
author | Miraclin T, Angel Aaron, Dr. Sanjith Sivadasan, Ajith Benjamin, Kenneth Harshad, Vanjare Nair, Shalini Abhilash, KPP AT, Prabhakar Mathew, Vivek |
author_facet | Miraclin T, Angel Aaron, Dr. Sanjith Sivadasan, Ajith Benjamin, Kenneth Harshad, Vanjare Nair, Shalini Abhilash, KPP AT, Prabhakar Mathew, Vivek |
author_sort | Miraclin T, Angel |
collection | PubMed |
description | BACKGROUND: Systemic hyper-coagulabilty leading to micro and macro thrombosis is a known complication of Coronavirus disease – 2019(COVID -19). The postulated mechanism appears to be the viral activation of endothelium, triggering the coagulation pathways. Thrombosis of the cerebral veins and sinuses (CVT), a potentially serious condition, has been increasingly reported with COVID – 19 infection. In this clinical study we attempt to describe the clinical profile, investigations and outcomes of patients with COVID- 19 associated CVT. METHODS: This is a single center prospective observational study from South India. The study included patients (aged >18 years) with concomitant COVID infection and CVT. The clinical, laboratory, imaging characteristics, management and outcomes were described and compared with COVID negative CVT patients. RESULTS: Out of 97 cases of CVT treated at our center during the first and second waves of the COVID pandemic 11/97 (11%) were COVID related CVT. Among these 11 patients, 9 (81%) had presented with only CVT related symptoms and signs and were tested positive for COVID - 19 infection during the pre-hospitalization screening. Respiratory symptoms were absent in 90% of the patients. Headache (100%) and seizures (90%) were the common presenting symptoms. The median time to diagnosis was 6 hours, from presentation to the emergency department. Transverse sinus was involved 10/11 (90%) and majority of them (9/11) had Haemorrhagic Venous Infarction (HVI). Acute inflammatory markers were elevated in comparison with non COVID CVT patients, with the mean serum D-dimer being 2462.75 ng/ml and the C-reactive protein was 64.5 mg/dl. Three patients (30%) underwent decompressive hemicraniectomy (DHC) because of large hemispheric HVI. All patients survived in the COVID CVT group while the mortality in the non COVID group was 4%. At 6 months follow up excellent outcome (modified Rankin Scale (mRS) score of 0–2) was noted equally in both groups. CONCLUSIONS: Symptoms and signs of CVT may be the only presentation of COVID-19 infection. Prompt recognition and aggressive medical management including DHC offers excellent outcomes. |
format | Online Article Text |
id | pubmed-8743463 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Elsevier Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-87434632022-01-10 Management and Outcomes of COVID – 19 Associated Cerebral Venous Sinus Thrombosis Miraclin T, Angel Aaron, Dr. Sanjith Sivadasan, Ajith Benjamin, Kenneth Harshad, Vanjare Nair, Shalini Abhilash, KPP AT, Prabhakar Mathew, Vivek J Stroke Cerebrovasc Dis Short Communication BACKGROUND: Systemic hyper-coagulabilty leading to micro and macro thrombosis is a known complication of Coronavirus disease – 2019(COVID -19). The postulated mechanism appears to be the viral activation of endothelium, triggering the coagulation pathways. Thrombosis of the cerebral veins and sinuses (CVT), a potentially serious condition, has been increasingly reported with COVID – 19 infection. In this clinical study we attempt to describe the clinical profile, investigations and outcomes of patients with COVID- 19 associated CVT. METHODS: This is a single center prospective observational study from South India. The study included patients (aged >18 years) with concomitant COVID infection and CVT. The clinical, laboratory, imaging characteristics, management and outcomes were described and compared with COVID negative CVT patients. RESULTS: Out of 97 cases of CVT treated at our center during the first and second waves of the COVID pandemic 11/97 (11%) were COVID related CVT. Among these 11 patients, 9 (81%) had presented with only CVT related symptoms and signs and were tested positive for COVID - 19 infection during the pre-hospitalization screening. Respiratory symptoms were absent in 90% of the patients. Headache (100%) and seizures (90%) were the common presenting symptoms. The median time to diagnosis was 6 hours, from presentation to the emergency department. Transverse sinus was involved 10/11 (90%) and majority of them (9/11) had Haemorrhagic Venous Infarction (HVI). Acute inflammatory markers were elevated in comparison with non COVID CVT patients, with the mean serum D-dimer being 2462.75 ng/ml and the C-reactive protein was 64.5 mg/dl. Three patients (30%) underwent decompressive hemicraniectomy (DHC) because of large hemispheric HVI. All patients survived in the COVID CVT group while the mortality in the non COVID group was 4%. At 6 months follow up excellent outcome (modified Rankin Scale (mRS) score of 0–2) was noted equally in both groups. CONCLUSIONS: Symptoms and signs of CVT may be the only presentation of COVID-19 infection. Prompt recognition and aggressive medical management including DHC offers excellent outcomes. Elsevier Inc. 2022-04 2022-01-10 /pmc/articles/PMC8743463/ /pubmed/35091267 http://dx.doi.org/10.1016/j.jstrokecerebrovasdis.2022.106306 Text en © 2022 Elsevier Inc. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. |
spellingShingle | Short Communication Miraclin T, Angel Aaron, Dr. Sanjith Sivadasan, Ajith Benjamin, Kenneth Harshad, Vanjare Nair, Shalini Abhilash, KPP AT, Prabhakar Mathew, Vivek Management and Outcomes of COVID – 19 Associated Cerebral Venous Sinus Thrombosis |
title | Management and Outcomes of COVID – 19 Associated Cerebral Venous Sinus Thrombosis |
title_full | Management and Outcomes of COVID – 19 Associated Cerebral Venous Sinus Thrombosis |
title_fullStr | Management and Outcomes of COVID – 19 Associated Cerebral Venous Sinus Thrombosis |
title_full_unstemmed | Management and Outcomes of COVID – 19 Associated Cerebral Venous Sinus Thrombosis |
title_short | Management and Outcomes of COVID – 19 Associated Cerebral Venous Sinus Thrombosis |
title_sort | management and outcomes of covid – 19 associated cerebral venous sinus thrombosis |
topic | Short Communication |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8743463/ https://www.ncbi.nlm.nih.gov/pubmed/35091267 http://dx.doi.org/10.1016/j.jstrokecerebrovasdis.2022.106306 |
work_keys_str_mv | AT miraclintangel managementandoutcomesofcovid19associatedcerebralvenoussinusthrombosis AT aarondrsanjith managementandoutcomesofcovid19associatedcerebralvenoussinusthrombosis AT sivadasanajith managementandoutcomesofcovid19associatedcerebralvenoussinusthrombosis AT benjaminkenneth managementandoutcomesofcovid19associatedcerebralvenoussinusthrombosis AT harshadvanjare managementandoutcomesofcovid19associatedcerebralvenoussinusthrombosis AT nairshalini managementandoutcomesofcovid19associatedcerebralvenoussinusthrombosis AT abhilashkpp managementandoutcomesofcovid19associatedcerebralvenoussinusthrombosis AT atprabhakar managementandoutcomesofcovid19associatedcerebralvenoussinusthrombosis AT mathewvivek managementandoutcomesofcovid19associatedcerebralvenoussinusthrombosis |